The Tortuous Road to an Ideal CGRP Function Blocker for the Treatment of Migraine

Author(s): Carl D. Davis, Cen Xu

Journal Name: Current Topics in Medicinal Chemistry

Volume 8 , Issue 16 , 2008

Become EABM
Become Reviewer
Call for Editor


The critical role of Calcitonin Gene-Related Peptide (CGRP) in migraine has been validated, with two small molecule CGRP antagonists BIBN4096BS and MK-0974 demonstrating efficacy in the reversal of acute migraine attack [1,2]. Multiple approaches have been taken to find the ideal agent that most effectively inhibits CGRPs function. Here, we have summarized the progress made in recent years, including the identification and optimization of an orally bioavailable small molecule CGRP receptor antagonist. We also describe other interventions such as scavenging of CGRP itself. The advantages and disadvantages of these distinct approaches are discussed.

Keywords: Migraine, CGRP receptor, BIBN4096BS, Merck-0974, CGRP scavenger, antibody, bioavailability, protein-binding

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Published on: 01 March, 2012
Page: [1468 - 1479]
Pages: 12
DOI: 10.2174/156802608786264218
Price: $65

Article Metrics

PDF: 21